Evaluation of the Symptomatic Treatment of Residual Neurological Symptoms in Wilson Disease

The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or not they were undergoing any treatment in addition to the common decoppering medication. Moreover, the effects of any symptomatic medication we...

Full description

Saved in:
Bibliographic Details
Published inEuropean neurology Vol. 64; no. 2; pp. 83 - 87
Main Authors Hölscher, Sara, Leinweber, Barbara, Hefter, Harald, Reuner, Ulrike, Günther, Peter, Weiss, Karl Heinz, Oertel, Wolfgang H., Möller, Jens Carsten
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.08.2010
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or not they were undergoing any treatment in addition to the common decoppering medication. Moreover, the effects of any symptomatic medication were analyzed. Two samples of WD patients were investigated either by a mailed questionnaire survey (n = 135) or by a retrospective analysis (n = 75). A considerable proportion of patients still suffered from neurological symptoms (n = 106, 50.5%), of whom a relatively small proportion was treated symptomatically (n = 33, 31.1%). The documented effects varied substantially, with anticholinergics and botulinum toxin (against dystonia) and primidone (against tremor) apparently being the most promising compounds. Further studies are required to analyze the symptomatic treatment of WD patients with residual neurological symptoms in more detail.
AbstractList The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or not they were undergoing any treatment in addition to the common decoppering medication. Moreover, the effects of any symptomatic medication were analyzed. Two samples of WD patients were investigated either by a mailed questionnaire survey (n = 135) or by a retrospective analysis (n = 75). A considerable proportion of patients still suffered from neurological symptoms (n = 106, 50.5%), of whom a relatively small proportion was treated symptomatically (n = 33, 31.1%). The documented effects varied substantially, with anticholinergics and botulinum toxin (against dystonia) and primidone (against tremor) apparently being the most promising compounds. Further studies are required to analyze the symptomatic treatment of WD patients with residual neurological symptoms in more detail. Copyright © 2010 S. Karger AG, Basel [PUBLICATION ABSTRACT]
The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or not they were undergoing any treatment in addition to the common decoppering medication. Moreover, the effects of any symptomatic medication were analyzed. Two samples of WD patients were investigated either by a mailed questionnaire survey (n = 135) or by a retrospective analysis (n = 75). A considerable proportion of patients still suffered from neurological symptoms (n = 106, 50.5%), of whom a relatively small proportion was treated symptomatically (n = 33, 31.1%). The documented effects varied substantially, with anticholinergics and botulinum toxin (against dystonia) and primidone (against tremor) apparently being the most promising compounds. Further studies are required to analyze the symptomatic treatment of WD patients with residual neurological symptoms in more detail.
The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or not they were undergoing any treatment in addition to the common decoppering medication. Moreover, the effects of any symptomatic medication were analyzed. Two samples of WD patients were investigated either by a mailed questionnaire survey (n = 135) or by a retrospective analysis (n = 75). A considerable proportion of patients still suffered from neurological symptoms (n = 106, 50.5%), of whom a relatively small proportion was treated symptomatically (n = 33, 31.1%). The documented effects varied substantially, with anticholinergics and botulinum toxin (against dystonia) and primidone (against tremor) apparently being the most promising compounds. Further studies are required to analyze the symptomatic treatment of WD patients with residual neurological symptoms in more detail. Copyright [copy 2010 S. Karger AG, Basel
Author Möller, Jens Carsten
Leinweber, Barbara
Oertel, Wolfgang H.
Reuner, Ulrike
Weiss, Karl Heinz
Günther, Peter
Hefter, Harald
Hölscher, Sara
Author_xml – sequence: 1
  givenname: Sara
  surname: Hölscher
  fullname: Hölscher, Sara
– sequence: 2
  givenname: Barbara
  surname: Leinweber
  fullname: Leinweber, Barbara
– sequence: 3
  givenname: Harald
  surname: Hefter
  fullname: Hefter, Harald
– sequence: 4
  givenname: Ulrike
  surname: Reuner
  fullname: Reuner, Ulrike
– sequence: 5
  givenname: Peter
  surname: Günther
  fullname: Günther, Peter
– sequence: 6
  givenname: Karl Heinz
  surname: Weiss
  fullname: Weiss, Karl Heinz
– sequence: 7
  givenname: Wolfgang H.
  surname: Oertel
  fullname: Oertel, Wolfgang H.
– sequence: 8
  givenname: Jens Carsten
  surname: Möller
  fullname: Möller, Jens Carsten
  email: carsten.moeller@med.uni-marburg.de
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20606453$$D View this record in MEDLINE/PubMed
BookMark eNqF0c1LwzAYBvAgE_ehB-8ixYt4qL5J2q45ypwfMBR04sFDSdJ3s7NtZtIK--_N2NzBi6fwJr88kDx90qlNjYQcU7ikNBZXAMBpAkmyR3o0YjQUgvIO6QHQKOTAWJf0nVv4MRbD9IB0GXgdxbxH3sffsmxlU5g6MLOg-cDgZVUtG1P5PR1MLcqmwrpZHz6jK_JWlsEjttaUZl5oP2y5C4o6eCtK54NuCofS4SHZn8nS4dF2HZDX2_F0dB9Onu4eRteTUHMhmjCPtNA8hhwUVTrXMeMq4lIrJZXgjMWKao0zKXM-zCUXICAVgmumMNWap3xAzje5S2u-WnRNVhVOY1nKGk3rsjQRcZqCYP_KYZR6mvjvHJCzP3JhWlv7Z2TDGDhwkSQeXWyQtsY5i7NsaYtK2lVGIVs3k-2a8fZ0G9iqCvOd_K3Cg5MN-JR2jnYHtvd_AHvEk4M
CODEN EUNEAP
CitedBy_id crossref_primary_10_3389_fneur_2021_783365
crossref_primary_10_1111_nyas_12437
crossref_primary_10_1007_s12035_023_03276_0
crossref_primary_10_1080_14737175_2019_1645009
crossref_primary_10_1080_21678707_2016_1188003
crossref_primary_10_1016_j_parkreldis_2019_02_016
crossref_primary_10_1186_s12883_018_1039_y
crossref_primary_10_3390_toxins13040241
crossref_primary_10_36290_vnl_2017_178
crossref_primary_10_1111_nyas_12372
crossref_primary_10_1007_s40261_022_01117_x
crossref_primary_10_1007_s11894_011_0227_3
crossref_primary_10_1016_j_cgh_2013_03_012
crossref_primary_10_1016_S2468_1253_17_30293_5
crossref_primary_10_4254_wjh_v13_i11_1552
crossref_primary_10_1007_s00702_017_1756_1
crossref_primary_10_1016_j_jceh_2018_08_009
crossref_primary_10_1016_S1474_4422_14_70190_5
crossref_primary_10_3389_fneur_2017_00559
crossref_primary_10_1016_j_brs_2019_05_014
crossref_primary_10_3390_ani12192703
crossref_primary_10_1186_2047_9158_1_23
crossref_primary_10_1080_14737175_2023_2268841
Cites_doi 10.1023%2FB%3AMEBR.0000043973.10494.85
10.1016%2Fj.parkreldis.2009.01.010
10.1053%2Fjhep.2003.50252
10.2165%2F00023210-200519030-00001
10.1034%2Fj.1600-0676.2003.00824.x
10.1007%2Fs00415-005-0720-4
10.1002%2Fmds.21761
10.1046%2Fj.1525-1373.2000.22305.x
ContentType Journal Article
Copyright 2010 S. Karger AG, Basel
Copyright 2010 S. Karger AG, Basel.
Copyright (c) 2010 S. Karger AG, Basel
Copyright_xml – notice: 2010 S. Karger AG, Basel
– notice: Copyright 2010 S. Karger AG, Basel.
– notice: Copyright (c) 2010 S. Karger AG, Basel
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TK
7X7
7XB
88E
88G
88I
8AF
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
M2M
M2P
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
S0X
7X8
DOI 10.1159/000316066
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
Science Database (Alumni Edition)
STEM Database
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Psychology Database
ProQuest Science Journals
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
SIRS Editorial
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest One Psychology
ProQuest Central Student
ProQuest Central Essentials
SIRS Editorial
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Psychology
MEDLINE - Academic
CrossRef
MEDLINE

Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1421-9913
EndPage 87
ExternalDocumentID 2136370141
10_1159_000316066
20606453
316066
Genre Evaluation Studies
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.GJ
0R~
0~5
0~B
29G
30W
325
34G
36B
39C
3O.
3V.
4.4
53G
5GY
5RE
7X7
88E
88I
8AF
8AO
8FI
8FJ
8UI
AAYIC
ABIVO
ABJNI
ABPAZ
ABUWG
ACGFO
ACGFS
ACGOD
ACPRK
ACPSR
ADAGL
ADBBV
ADFRT
ADGES
AENEX
AEYAO
AFJJK
AFKRA
AFOSN
AHMBA
AI.
ALDHI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZPMC
AZQEC
BENPR
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CYUIP
DU5
DWQXO
E0A
EBS
EJD
EMB
EMOBN
F5P
FB.
FYUFA
GNUQQ
HCIFZ
HMCUK
HZ~
IY7
KUZGX
M1P
M2M
M2P
N9A
O1H
O9-
P2P
PQQKQ
PROAC
PSQYO
PSYQQ
RIG
RKO
RXVBD
S0X
SV3
UJ6
UKHRP
VH1
X7M
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
7XB
8FK
K9.
PQEST
PQUKI
PRINS
Q9U
7X8
ID FETCH-LOGICAL-c399t-d4c9c350d0b1bcdc523b43acbbab93225b1ccefaad37da390908993c2be8cc383
IEDL.DBID BENPR
ISSN 0014-3022
IngestDate Thu Jul 25 08:27:20 EDT 2024
Fri Aug 16 07:42:17 EDT 2024
Thu Oct 10 16:39:33 EDT 2024
Wed Sep 18 12:52:42 EDT 2024
Sat Sep 28 07:50:45 EDT 2024
Thu Aug 29 12:04:41 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Wilson disease
Symptomatic treatment
Movement disorder
Language English
License Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Copyright 2010 S. Karger AG, Basel.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c399t-d4c9c350d0b1bcdc523b43acbbab93225b1ccefaad37da390908993c2be8cc383
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
OpenAccessLink https://tud.qucosa.de/api/qucosa%3A27508/attachment/ATT-0/
PMID 20606453
PQID 750303966
PQPubID 41501
PageCount 5
ParticipantIDs crossref_primary_10_1159_000316066
pubmed_primary_20606453
karger_primary_316066
proquest_miscellaneous_748958600
proquest_miscellaneous_869588092
proquest_journals_750303966
PublicationCentury 2000
PublicationDate 2010-08-00
PublicationDateYYYYMMDD 2010-08-01
PublicationDate_xml – month: 08
  year: 2010
  text: 2010-08-00
PublicationDecade 2010
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
– name: Switzerland
– name: Basel
PublicationTitle European neurology
PublicationTitleAlternate Eur Neurol
PublicationYear 2010
Publisher S. Karger AG
Publisher_xml – name: S. Karger AG
References Leinweber B, Möller JC, Scherag A, Reuner U, Günther P, Lang CJG, Schmidt HHJ, Schrader C, Bandmann O, Czlonkowska A, Oertel WH, Hefter H: Evaluation of the Unified Wilson’s Disease Rating Scale (UWDRS) in German patients with treated Wilson’s disease. Mov Disord 2008;23:54–62.1796079910.1002%2Fmds.21761
Ferenci P: Pathophysiology and clinical features of Wilson disease. Met Brain Dis 2004;19:229–239.1555441910.1023%2FB%3AMEBR.0000043973.10494.85
Roberts EA, Schilsky ML: A practice guideline on Wilson disease. Hepatology 2003;37:1475–1492.1277402710.1053%2Fjhep.2003.50252
Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D, Berr F: Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003;23:139–142.1295587510.1034%2Fj.1600-0676.2003.00824.x
Brewer GJ: Recognition, diagnosis, and management of Wilson’s disease. Proc Soc Exp Biol Med 2000;223:39–46.1063295910.1046%2Fj.1525-1373.2000.22305.x
Svetel M, Potrebic A, Pekmezovic T, Tomic A, Kresojevic N, Jesic R, Dragasevic N, Kostic VS: Neuropsychiatric aspects of treated Wilson’s disease. Parkinsonism Relat Disord 2009;15:772–775.1955964010.1016%2Fj.parkreldis.2009.01.010
Brewer GJ: Neurologically presenting Wilson’s disease: epidemiology, pathophysiology and treatment. CNS Drugs 2005;19:185–192.1574017410.2165%2F00023210-200519030-00001
Czlonkowska A, Tarnacka B, Litwin T, Gajda J, Rodo M: Wilson’s disease – cause of mortality in 164 patients during 1992–2003 observation period. J Neurol 2005;252:698–703.1574210810.1007%2Fs00415-005-0720-4
Barthel M, Hermann W, Kluge R, Hesse S, Collingridge DR, Wagner A, Sabri O: Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. AJNR Am J Neuroradiol 2003;24:234–238.12591639
ref8
ref7
ref4
ref3
ref6
ref5
ref2
ref1
References_xml – ident: ref1
  doi: 10.1023%2FB%3AMEBR.0000043973.10494.85
– ident: ref8
  doi: 10.1016%2Fj.parkreldis.2009.01.010
– ident: ref2
  doi: 10.1053%2Fjhep.2003.50252
– ident: ref5
  doi: 10.2165%2F00023210-200519030-00001
– ident: ref3
  doi: 10.1034%2Fj.1600-0676.2003.00824.x
– ident: ref6
  doi: 10.1007%2Fs00415-005-0720-4
– ident: ref7
  doi: 10.1002%2Fmds.21761
– ident: ref4
  doi: 10.1046%2Fj.1525-1373.2000.22305.x
SSID ssj0015978
Score 2.127266
Snippet The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or...
SourceID proquest
crossref
pubmed
karger
SourceType Aggregation Database
Index Database
Publisher
StartPage 83
SubjectTerms Adult
Aged
Anti-Dyskinesia Agents - therapeutic use
Botulinum Toxins - therapeutic use
Cholinergic Antagonists - therapeutic use
Female
Health Surveys
Hepatolenticular Degeneration - complications
Humans
Male
Middle Aged
Nervous System Diseases - drug therapy
Nervous System Diseases - etiology
Original Paper
Retrospective Studies
Surveys and Questionnaires
Treatment Outcome
Young Adult
Title Evaluation of the Symptomatic Treatment of Residual Neurological Symptoms in Wilson Disease
URI https://karger.com/doi/10.1159/000316066
https://www.ncbi.nlm.nih.gov/pubmed/20606453
https://www.proquest.com/docview/750303966
https://search.proquest.com/docview/748958600
https://search.proquest.com/docview/869588092
Volume 64
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD64TcQX8TK1TkcQX4ttk17yJF42hrAhc4OBD6W5FERs59o9-O9N2rTgg74mBwInycl38p18AbhxEuoJTALbZ5irBEVSmxIi7ZCpwyjxOZNCP3CezoLJkjyv_JWpzSlMWWUTE6tALXKu78hvNd_mYAXO79Zftv40SpOr5geNDvQ8l2iWtvcwmr3MWxpBoWUTivX1v-cZaSHVrl8wYFej918H0u6Hrr_e_A03q2NnfAgHBi-i-3qCj2BHZsewNzWM-Am8jVq5bpSnSME59Pr9uS7zSooVLZo6ct05l0X19ApVihwm6DXmBXrPUC3eiJ5q1qYPy_Fo8TixzYcJNlc4o7QF4ZRj3xEOcxkXXCWZjOCEM5YwqncuczmXaZIIHIoEU6ci_TD3mIw4V7nqKXSzPJPngGRKVGLjpjwMUsI0igqxios4CoRPOA4suG68Fq9rXYy4yid8GreutaBf-7M1adoHjXtjs2WKuJ1gC1Dbq9a6JjCSTOZbZUIi6kcKov1tEgXKInKoZ8FZPW_t2J4TaHE-fPHv6APYrwsEdI3fJXTLzVZeKdxRsiF0wlU4NGvsB26c16g
link.rule.ids 315,786,790,12083,21416,27955,27956,31752,31753,33777,33778,43343,43838,74100,74657
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLZgIOCCeAwozwhxrWib9JETQrBpwLYDbNIkDlXzqIQQ7Vi7A_-epE0rcRjXxFIkJ7E_x_YXgBsnoZ7AJLB9hrkKUCS1KSHSDplyRonPmRS6wXk0DgZT8jzzZ6Y2pzBllY1NrAy1yLl-I7_V-TYHK3B-N_-29adROrlqftBYhw2CMdHHPJy18ZZy1I0h1o__nmeIhdS47l_Arsbuf9zR5qeuvl6sBpuV0-nvwa5Bi-i-3t59WJPZAWyNTD78EN57LVk3ylOkwBx6-_mal3lFxIomTRW5nnyVRdV4hSo-DmPyGvECfWSopm5Ej3XOpgvTfm_yMLDNdwk2VyijtAXhlGPfEQ5zGRdchZiM4IQzljCq7y1zOZdpkggcigRTp0r5Ye4xGXGuItUj6GR5Jk8AyZSosMZNeRikhGkMFWJlFXEUCJ9wHFhw3WgtntesGHEVTfg0blVrQbfWZyvSjJ816o3NhSnidnstQO2sOuk6fZFkMl8qERJRP1IAbbVIFCiJyKGeBcf1vrVre06gqfnw6b-rX8H2YDIaxsOn8csZ7NSlArra7xw65WIpLxQCKdlldc5-AfGx2Eg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ZS8QwEB68WHwRj1XrGcTXst0mPfIk4rp4LqK7sOBDaY6CiO26x4P_3kmbFnxYX5OBwCSZ-SYz-Qbg0ku5rygL3UBQiQGK5i5nTLuRQGeUBlJoZT44Pw_CuxF7GAdjSyk0s2WVtU0sDbUqpHkj75h8m0cRnHcyWxXx0utfTb5d00DKJFptN41VWEcn6ZkuDtG4ib3QaddG2SQCfN-SDOG4-ctAuwbH_3FNG5-mEnu6HHiWDqi_DVsWOZLraqt3YEXnu9B6trnxPXi_bYi7SZERBHbk7edrMi9KUlYyrCvKzeSrnpWfsEjJzWHNXy0-Ix85qWgcSa_K37Rh1L8d3ty5tnWCKxFxzF3FJJc08JQnukIqieGmYDSVQqSCmzssulLqLE0VjVRKuVem_6j0hY6lxKh1H9byIteHQHTGMMTpZjIKMyYMnoooWkgahypgkoYOXNRaSyYVQ0ZSRhYBTxrVOtCu9NmI1OPHtXoTe3lmSbPVDpBmFk-9SWWkuS4WKMJiHsQI1paLxCFKxB73HTio9q1Z2_dCQ9NHj_5d_RxaeMSSp_vB4zFsVlUDpvDvBNbm04U-RTAyF2flMfsF9Y3cdA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+symptomatic+treatment+of+residual+neurological+symptoms+in+Wilson+disease&rft.jtitle=European+neurology&rft.au=H%C3%B6lscher%2C+Sara&rft.au=Leinweber%2C+Barbara&rft.au=Hefter%2C+Harald&rft.au=Reuner%2C+Ulrike&rft.date=2010-08-01&rft.eissn=1421-9913&rft.volume=64&rft.issue=2&rft.spage=83&rft_id=info:doi/10.1159%2F000316066&rft_id=info%3Apmid%2F20606453&rft.externalDocID=20606453
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-3022&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-3022&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-3022&client=summon